Zentalis Pharmaceuticals ZNTL 深 沪
等待开盘 08-18 09:30:00 美东时间
1.59
+0.110
+7.43%
华盛通- 最 高1.6994
- 今 开1.50
- 成交量 148.39万股
- 最 低 1.50
- 昨 收 1.48
- 总市值 1.14亿
- 52周最高 5.44
- 市盈率 静 --
- 换手率 2.06%
- 52周最低 1.01
- 委 比 60.73%
- 总股本 7195.19万
- 历史最高 87.19
- 量 比 2.52
- 振 幅 13.47%
- 历史最低 1.01
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $5
Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $6 to $5.
08-07 22:38
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals reported positive progress in its DENALI Phase 2 trial for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by end-2026. The company has $303.4 million in cash, supporting operations into late 2027. Azenosertib demonstrated anti-tumor activity and is being evaluated for accelerated approval. R&D expenses decreased by $20.8 million, and G&A expenses decreased by $8.3 mi...
08-06 20:05
Responding to the White House AI Action Plan, ZenaTech’s ZenaDrone Launches Zena AI, Inc., a Specialized AI Development Center for US Defense and Homeland Security Applications
VANCOUVER, BC – ZenaTech, Inc. announced the formation of Zena AI, Inc., an AI Development Center under its ZenaDrone US subsidiary. Zena AI will focus on developing advanced AI software solutions for the US Department of Defense and Homeland Security, in response to the White House’s AI Action Plan and related Executive Orders released on July 23. The initiative aims to accelerate the development of American-made AI systems and boost global expo...
07-29 12:15
ZenaTech Poised to Benefit from Historic US Defense Spending─$33 Billion for Drone and Autonomy Investments in ‘One Big Beautiful Bill’
ZenaTech anticipates significant benefits from the recently passed One Big Beautiful Bill Act, which allocates $33 billion for advanced drones and defense modernization. The bill includes $150 billion in defense spending and restores R&D incentives, enhancing ZenaTech's financial position. ZenaTech, a leader in AI drones and DaaS, plans to leverage these opportunities to grow its defense and government agency partnerships. The company's products,...
07-08 12:00
ZenaTech Signs Offer to Acquire North Carolina Land Surveying Company to Expand State Operations and Government Customers
ZenaTech Inc. has agreed to acquire a North Carolina-based land surveying company with a strong government client base. This strategic move aims to enhance regional market penetration and growth in the U.S. Southeast while supporting its Drone as a Service (DaaS) expansion. The acquisition focuses on integrating AI-powered drones into land survey workflows for improved efficiency. ZenaTech has completed five acquisitions and plans 20 more within ...
06-26 12:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted 137,400 non-qualified stock options to four new employees on June 2, 2025, under its 2022 Inducement Plan. The options have an exercise price of $1.28 per share, vest over four years, and are contingent on continued employment. The company focuses on developing a first-in-class WEE1 inhibitor for ovarian cancer and other cancers.
06-02 21:00
ZenaTech Provides Quantum Computing Update on ‘Clear Sky' Weather Forecasting Project─AI Drone Swarms to Combat Steep Rise in Billion Dollar Extreme Weather Events
ZenaTech announces its "Clear Sky" project using AI-powered drone swarms and quantum computing for weather prediction, targeting extreme events like tornadoes. The company plans to expand its quantum team by 10 engineers to accelerate development. CEO Shaun Passley highlights the need for improved weather forecasting, citing $417 billion in global losses from 2024 disasters. AI drones collect real-time atmospheric data, enhancing prediction accur...
05-27 12:15
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $10 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $10 price target.
05-15 19:57
Zentalis Pharma Q1 EPS $(0.67) Misses $(0.63) Estimate
Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.63) by 6.35 percent. This is a 578.57 percent decrease over earnings of $0.14 per share from
05-15 04:20
